

DAFTAR PUSTAKA

1. Care, D., & Suppl, S. S. (2025). Introduction and Methodology: Standards of Care in Diabetes—2025. *Diabetes Care*, 47(January), S1–S4. <https://doi.org/10.2337/dc24-SINT>
2. Perkumpulan Endokrinologi Indonesia. (2021). Pedoman Pengelolaan dan Pencegahan Diabetes Melitus Tipe 2 Dewasa di Indonesia 2021. *Global Initiative for Asthma*, 46. www.ginasthma.org.
3. Laporan Nasional Riskesdas. (2018). Laporan Riskesdas 2018 Nasional.pdf. In *Lembaga Penerbit Balitbangkes* (p. 156).
4. Jefferson, N. M. (2019). A patient's view on exercise and ESKD. *Clinical Journal of the American Society of Nephrology*, 14(2), 171. <https://doi.org/10.2215/CJN.00150119>
5. Hidayah, L., & Adhitama, L. F. (2024). Evaluasi Pengobatan Pasien Gagal Ginjal Terhadap Penggunaan Obat Nefrotoksik Di Rs Aura Syifa Kota Kediri. *Java Health Journal*, 8, 2338–5936.
6. Coates, P. T., Devuyst, O., Wong, G., Okusa, M., Oliver, J., York, N., Pattaro, C., Peixoto, A., Haven, W., Perazella, M., Haven, N., Peti-peterdi, J., Angeles, L., Quaggin, S., Reeves, W. B., Antonio, S., Reich, H., Rhee, C., Ross, M., ... Lu, C. (2020). *I n t e r n a t i o n a l*. 98(4).
7. PNPk Gagal Ginjal Kronik. (2023). Keputusan Menteri Kesehatan Republik Indonesia Nomor HK.01.07/MENKES/328/2020 Tentang pencegahan dan pengendalian. Keputusan Menteri Kesehatan Republik Indonesia Nomor HK, 1(07). *Keputusan Menteri Kesehatan Republik Indonesia*, 11, 1–189. <https://www.kemkes.go.id/id/pnpk-2023---tata-laksana-penyakit-ginjal-kronik>
8. Sherwood, L. (2020). *Human Physiology PDF*.
9. Rahayu, M., Supriyanta, B., Silalahi, D. M. D., Abdul, N. A., & Nurlina, W. O. (2023). *ILMU BIOMEDIK UNTUK PERAWAT*.
10. Hall & Guyton (2011). Textbook of Medical Physiology. Stingelin L, editor. Amerika Serikat: Saunders Elsevier.
11. Agustina Julisawaty E, Munich Heindari Ekasari D, Hurnaningsih. Aplikasi Augmented Reality Tentang Fungsi Organ Ginjal Manusia Dan Cara Menjaga Kesehatannya. Univ Gunadarma Jl Margonda Raya [Internet]. 2020;4(1):16424. Tersedia pada: <https://ejournal.jakstik.ac.id/files/journals/2/articles/sentik2020/289/submission/proof/289-131078-1-10-20201030.pdf>
12. Gama Bagus Kuntoadi, K.KG M. Buku Anatomi Fisiologi 2. 1 ed. Pantera; 2022. 5–6 hal.

13. Rini DS, Kesehatan P, Kesehatan K. *Anatomi Fisiologi Tubuh Manusia*. Padang: PT Global Eksekutif Teknologi; 2023.
14. Sherwood L. *Fisiologi Manusia : dari sel ke sistem*. 8 ed. Sherwood L, editor. Jakarta: EGC penerbit buku kedokteran; 2014.
15. KDIGO. *Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease*. Kidney International Supplements; 2020.
16. Pernefri.(2023).Konsensus Gangguan Ginjal Akut. Jakarta:Pernefri.
17. KDIGO. (2012). *KDIGO Clinical Practice Guideline for Acute Kidney Injury*. Kidney International Supplements, 2(1), 1–138.
18. Bellomo, R., Kellum, J. A., & Ronco, C. (2017). *Acute kidney injury*. The Lancet, 394(10212), 1949–1964.
19. Susantitaphong, P., Cruz, D. N., Cerda, J., Abulfaraj, M., Alqahtani, F., Koulouridis, I., & Jaber, B. L. (2013). *World incidence of AKI: A meta-analysis*. Clinical Journal of the American Society of Nephrology, 8(9), 1482–1493.
20. Hoste, E. A. J., Bagshaw, S. M., Bellomo, R., Cely, C. M., Colman, R., Cruz, D. N., ... & Kellum, J. A. (2015). *Epidemiology of acute kidney injury in critically ill patients: The multinational AKI-EPI study*. Intensive Care Medicine, 41(8), 1411–1423.
21. Wonnacott, A., Meran, S., Amphlett, B., Talabani, B., & Phillips, A. (2014). *Epidemiology and outcomes of acute kidney injury in hospitalized patients: A retrospective cohort study*. International Journal of Clinical Practice, 68(10), 1301–1310.
22. Kellum, J. A., & Lameire, N. (2013). *Diagnosis, evaluation, and management of acute kidney injury: A KDIGO summary*. Critical Care, 17(1), 204.
23. Tandukar, S., & Palevsky, P. M. (2019). *Acute kidney injury: What nephrologists need to know*. New England Journal of Medicine, 380(2), 190–201.
24. Gowda, S., & Channabasappa, S. (2017). *Acute kidney injury: Pathophysiology and etiology overview*. Journal of Clinical and Diagnostic Research, 11(12), 1–5.
25. Taal MW, Chertow GM, Marsden PA, Skorecki K, Yu ASL, Brenner BM.(2020). *Brenner & Rector's The Kidney*. 11th Edition. Philadelphia: Elsevier.
26. Pangalila, F. J. V. (n.d.). *Konsensus Penatalaksanaan ACUTE KIDNEY INJURY*.

27. Kane-Gill SL, Goldstein SL. Drug-Induced Acute Kidney Injury: A Focus on Risk Assessment for Prevention. *Crit Care Clin* [Internet]. 2015;31(4):675–84.
28. Braund R. Renal Medicine and Clinical Pharmacy. 1 ed. Rhiannon Braund, editor. Dunedin, New Zealand; 2020.
29. Schetz M, Dasta J, Goldstein S, Golper T. *Drug-induced acute kidney injury*. *Curr Opin Crit Care*. 2005;11(6):555–65.
30. Naughton CA. Drug-induced nephrotoxicity. *Am Fam Physician*. 2008;78(6):743–50.
31. Perazella MA. Drug-induced nephrotoxicity: an update. *Expert Opin Drug Saf*. 2005;4(4):689–706.
32. Schetz M, Dasta J, Goldstein S, Golper T. Drug-induced acute kidney injury. *Curr Opin Crit Care*. 2005;11(6):555–65.
33. Pannu N, Nadim MK. An overview of drug-induced acute kidney injury. *Crit Care Med*. 2008;36(4 Suppl):S216–23.
34. Zager RA. Pathogenetic mechanisms in nephrotoxic acute renal failure. *Cardiovasc Hematol Agents Med Chem*. 2008;6(3):237–41.
35. Farooq S, Mujtaba MA, et al. Medication-induced nephrotoxicity and its clinical significance. *Clin Nephrol*. 2021;95(1):1–10.
36. Zuk, A., & Bonventre, J. V. (2016). *Acute Kidney Injury*. 293–307.
37. Rev, N., & Discov, D. (2016). *HHS Public Access*. 14(1), 29–44.
38. Dziedziejko, V., Kajdy, A., Stefa, K., & Kwiatkowski, S. (2021). *The Mechanism of Drug Nephrotoxicity and the Methods for Preventing Kidney Damage*.
39. Moledina DG, Perazella MA. Drug-induced acute interstitial nephritis. *Clin J Am Soc Nephrol*. 2017;12(12):2046–2049.
40. Perazella MA. Crystal-induced acute kidney injury. *Clin J Am Soc Nephrol*. 2015;10(12):2250–2259.
41. Kellum, J. (2021). *Acute Kidney Injury*. The Lancet.
42. McCullough, P. A. (2016). *Contrast-induced acute kidney injury*. *Journal of American College of Cardiology*, 68, 1465–1473.
43. Pasternak, B., et al. (2019). *Nephrotoxicity of amphotericin B formulations*. *Clinical Infectious Diseases*, 68, 1495–1503.
44. Holditch, S. J., et al. (2019). *Cisplatin nephrotoxicity mechanisms and prevention strategies*. *Nature Reviews Nephrology*, 15, 245–257.
45. Naesens, M., Kuypers, D. R., & Sarwal, M. (2009). *Calcineurin inhibitor nephrotoxicity*. *Clinical Journal of the American Society of Nephrology*, 4(2), 481–508.

46. Report, A. (2020). *Therapeutic monitoring of vancomycin for serious A revised consensus guideline and review by the American Society of America , the Pediatric Infectious Diseases Society ,.* 77(11), 835–863.
47. Cooper, R. D., et al. (2010). *Renal toxicity of tenofovir disoproxil fumarate.* Kidney International, 78(11), 1063–1069.
48. DeBelle, F. D., Vanherweghem, J. L., & Nortier, J. L. (2008). *Aristolochic acid nephropathy: A worldwide problem.* Kidney International, 74(2), 158–169.
49. Braund, R. (ed.) (2020) *Renal Medicine and Clinical Pharmacy.* 1st ed. Dunedin, New Zealand.
50. Wu, H. and Huang, J. (2018) ‘Drug-Induced Nephrotoxicity: Pathogenic Mechanisms, Biomarkers and Prevention Strategies’, pp. 559–567.
51. Mody, H., Ramakrishnan, V., Chaar, M., Lezeau, J., Rump, A., Taha, K. *etal.*(2020) ‘A review on drug-induced nephrotoxicity: pathophysiological mechanisms, drug classes, clinical management, and recent advances in mathematical modeling and simulation approaches’, *Clinical Pharmacology in Drug Development*, 9, pp. 896–909.
52. Risch, L. and Hess, B. (2013) ‘Acute kidney injury: A guide to diagnosis and management’, *Therapeutische Umschau*, 70(8), pp. 457–464.
53. Dipiro, J.T., Yee, G.C., Posey, L.M., Haines, S.T., Nolin, T.D. and V., E. (2020) *Pharmacotherapy: A pathophysiologic approach.* 11th edn. USA: McGraw-Hill.
54. Galicia-garcia, U., Benito-vicente, A., Jebari, S., & Larrea-sebal, A. (n.d.). *Pathophysiology of Type 2 Diabetes Mellitus.* 1–34.
55. *Volume 3 Nomor 1 | 2025 | 44.* (2025). 3, 44–63.
56. Ru, E., Ec, O., & Gi, M. (2025). *Complications Associated with Type 2 Diabetes Mellitus , Pathophysiology , Diagnosis and Management : A Concise Review of Current Literature.* 3214, 201–244.
57. Doman PE, An PEL. *Pedoman Pelayanan Kefarmasian Pada Pasien Diabetes Melitus.* Kemenkes RI. 2019. 85 p.
58. Kautzky-willer, A., & Pacini, G. (2016). *and Complications of Type 2 Diabetes Mellitus.* 37(June), 278–316. <https://doi.org/10.1210/er.2015-1137>
59. Magdalena, S., Torus, B., Halim, R., Butar, M. B., & Syukri, M. (2026). *Faktor Risiko Diabetes Melitus Tipe II pada Wanita Kelompok Umur ≥ 15 Tahun di Indonesia Analisis Data Survei Kesehatan Indonesia 2023 Desain dan Data Penelitian Penelitian ini merupakan analisis data sekunder (secondary data analysis) dengan.* 2(Dm).
60. Padang, M. D. (2020). *Karakteristik Penderita Diabetes Melitus Tipe 2 dengan Komplikasi Nefropati Diabetik.* 218–226.

61. Guideline, C. P., & Disease, C. K. (2024). *KDIGO 2024 CLINICAL PRACTICE GUIDELINE FOR THE EVALUATION AND MANAGEMENT*. 105(4).
62. Guideline, C. P., & Disease, C. K. (2024). *KDIGO 2024 CLINICAL PRACTICE GUIDELINE FOR THE EVALUATION AND MANAGEMENT*. 105(4).
63. National Kidney Foundation. How to Classify CKD. National Kidney Foundation CKD Classification
64. Care, I., Ehrmann, S., Helms, J., Joret, A., Lefevre, L. M., Quenot, J. P., Herbrecht, J. E., Lefevre, D. B., Robert, R., Desachy, A., & Bellec, F. (2019). Nephrotoxic drug burden among 1001 critically ill patients : impact on acute kidney injury. *Annals of Intensive Care*, 1–9.
65. Pazhayattil, G. S. (2014). *Drug-induced impairment of renal function*. 457–468
66. Campbell, R. E., Chen, C. H., & Edelstein, C. L. (2023). Overview of Antibiotic-Induced Nephrotoxicity. *Kidney International Reports*, 8(11), 2211–2225.
67. Abishek, A., & Venkateswaramurthy, N. (2023). *Review Article A review on antibiotics induced nephrotoxicity*. 12(4), 600–606.
68. Padang, M. D. (2020). *Karakteristik Penderita Diabetes Melitus Tipe 2 dengan Komplikasi Nefropati Diabetik*. 218–226.
69. Rachmaini, F., Amalia, L., & Rahayu, C. (2020). *Profil Terapi Antihipertensi dan Antihiperlipidemia Terhadap Fungsi Ginjal Pasien Diabetes Melitus Tipe 2 dengan Komplikasi Penyakit Ginjal Kronis di RSUP Dr . Hasan Sadikin Kidney Function in Type 2 Diabetes Mellitus Patients with Chronic Kidney Disease Complication at Dr . Hasan Sadikin Hospital*. 7(July 2018), 17–27.
70. Fadhillah, H., Kasumawati, F., & Yuningsih, D. (2023). *Analisis Tingkat Kepatuhan Penggunaan Obat Antidiabetes Oral Pada Pasien Diabetes Melitus Tipe II*. 07(02), 121–128.
71. East, I. (2020). *Kepatuhan Terhadap Pengobatan Pasien Diabetes Melitus Tipe 2 di Puskesmas Jakarta Timur (The Compliance On Their Medication Of Type 2 Diabetes Mellitus Patients In The Public*. 6(1), 94–103. <https://doi.org/10.22487/j24428744.2020.v6.i1.15002>
72. Pada, K., Diabetes, P., Tipe, M., & Rsud, D. I. (2024). *HUBUNGAN KEPATUHAN PENGOBATAN TERHADAP OUTCOME*. 5, 13202–13210.
73. Fadhillah, H., Kasumawati, F., & Yuningsih, D. (2023). *Analisis Tingkat Kepatuhan Penggunaan Obat Antidiabetes Oral Pada Pasien Diabetes Melitus Tipe II*. 07(02), 121–128.
74. Härmark, L., Wiel, H. E. Van Der, Groot, M. C. H. De, & Grootheest, A. C. Van. (2007). *Proton pump inhibitor-induced acute interstitial nephritis*. *July*, 819–823. <https://doi.org/10.1111/j.1365-2125.2007.02927.x>

75. Sampathkumar, K., Ramalingam, R., Prabakar, A., & Abraham, A. (2013). *Acute interstitial nephritis due to proton pump inhibitors*. 23(4), 304–307. <https://doi.org/10.4103/0971-4065.114487>
76. Blank, M., Parkin, L., Paul, C., & Herbison, P. (2014). A nationwide nested case-control study indicates an increased risk of acute interstitial nephritis with proton pump inhibitor use. *Kidney International*, 86(4), 837–844.
77. Alicic, R. Z., Rooney, M. T., & Tuttle, K. R. (2017). *Diabetic Kidney Disease*. 12(18).
78. *Clinical Therapeutics_20260625* (1). (n.d.).
79. Zhang, X., Donnan, P. T., Bell, S., & Guthrie, B. (2017). *Non-steroidal anti-inflammatory drug induced acute kidney injury in the community dwelling general population and people with chronic kidney disease : systematic review and meta-analysis*. 1–12.
80. Kom, I. A. R. Y., Dongelmans, D. A., Abu-hanna, A., Schut, M. C., Lange, D. W. De, Roon, E. N. Van, Jonge, E. De, Bouman, C. S. C., Keizer, N. F. De, Jager, K. J., Klopotoska, J. E., & Study, R. (2023). Acute kidney injury associated with nephrotoxic drugs in critically ill patients : a multicenter cohort study using electronic health record data. *Clinical Kidney Journal*, 16(12), 2549–2558.
81. Kusumawardani, L. A. (2025). *Assessment of Potentially Nephrotoxic Drug Prescriptions in Chronic Kidney Disease Outpatients at a Hospital in Indonesia*. February, 59–69.
82. Ingrassiotta, Y., Sultana, J., Giorgianni, F., Caputi, A. P., Arcoraci, V., Tari, D. U., Linguiti, C., Perrotta, M., Nucita, A., Pellegrini, F., Fontana, A., Cavagna, L., Santoro, D., & Trifiro, G. (2014). *The Burden of Nephrotoxic Drug Prescriptions in Patients with Chronic Kidney Disease : A Retrospective Population-Based Study in Southern Italy*. 9(2), 1–8. <https://doi.org/10.1371/journal.pone.0089072>